1 - 5 of 46
04.03.2010
BB BIOTECH AG published its Annual Report for 2009 today. The company takes an overall positive view of the past fiscal year and, in light of the biotech industry’s continued high innovation, above-average growth rates and historically low valuation, it also looks to 2010 with confidence.
02.03.2010
• Result nearly balanced excluding extraordinary effects
• Extraordinary depreciation and value adjustments result in Group net loss of CHF 95.1 million
• Liquidity remains sound with a strong equity base (tier 1 ratio: 56.5%)
• Dividend of CHF 4 per registered share recommended again - dividend yield of 12.1%
• Serge Monnerat new CEO at Bank am Bellevue
• Extraordinary depreciation and value adjustments result in Group net loss of CHF 95.1 million
• Liquidity remains sound with a strong equity base (tier 1 ratio: 56.5%)
• Dividend of CHF 4 per registered share recommended again - dividend yield of 12.1%
• Serge Monnerat new CEO at Bank am Bellevue
12.02.2010
Bellevue Group has agreed to purchase for the amount of USD 2.5 Mio a 10% minority interest
in the US Broker Auerbach Grayson & Co in New York. A designated agreement was now signed
by the two houses. Auerbach Grayson is a specialised Broker in the US for worldwide research
together with foreign partner banks.
in the US Broker Auerbach Grayson & Co in New York. A designated agreement was now signed
by the two houses. Auerbach Grayson is a specialised Broker in the US for worldwide research
together with foreign partner banks.
03.02.2010
Der BB Entrepreneur Switzerland Fonds von Bellevue Asset Management wurde anlässlich der Lipper Fund Awards Switzerland 2010 von Thomson-Reuters zum besten Schweizer Aktienfonds über drei Jahre ausgezeichnet. Dies ist eine Bestätigung für das fokussierte Anlagekonzept des Fonds, der vorwiegend in börsenkotierte familien- und eigentümergeführte Unternehmen der Schweiz investiert.
28.01.2010
BB BIOTECH AG up 14.9% in 2009 - Portfolio broadened
